Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn by Earle A. Chiles Research Institute, adding:
“As Liver Cancer Awareness month draws to a close, I want to note how excited I am to have Dr. Binbin Zheng-Lin as a colleague in the Earle A. Chiles Research Institute and the Robert W Franz Cancer Center – a component of the Providence Cancer Institute. Dr. Zheng brings a great background and lots of enthusiasm, energy, and hope to address the problem of Liver Cancer. Looking forward to working closely with Dr. Zheng to apply advances in our understanding of Cancer’s DarkMatter, to address the problem of liver cancer/HCC.
Towards that end, phase I clinical data suggest that a vaccine technology invented at the Earle A. Chiles Research Institute and developed, with National Cancer Institute (NCI) funding, into a clinical vaccine by UbiVac, induces immune responses to cancer’s DarkMatter and, in a trial supported by Incyte, has tripled response rates in HeadAndNeckCancer. Dr. Rom Leidner will present updates on this trial in the DarkMatter session on Nov. 8th at SITC2025.
I plan to work with Dr. Zheng to design a trial and garner support that will enable us to have the world’s first Dark Matter combination immunotherapy trial for patients with liver cancer.
Liver cancer is a tough disease, and we are looking for Pharma partners with the right agent that might assist/support productive anti-cancer immune responses in the liver. We know the DPV001 vaccine and anti-PD1 induce these immune cells in patients with NSCLC and HNSCC, and DPV-001 has >100 antigens overexpressed by HCC, but we also appreciate the environment of the liver poses additional hurdles. If you have ideas or interests, I will be at SITC2025.
Need to thank the Providence Portland Medical Foundation and the many philanthropists who support our efforts to rapidly move the latest scientific breakthroughs into first-in-human clinical trials that hold promise for defeating cancer.”
Quoting Earle A. Chiles Research Institute’s post:
“October is Liver Cancer Awareness Month, an opportunity to highlight how clinical trials and immunotherapy research are improving outcomes for people with the disease.
At Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute, researchers are advancing cancer immunotherapy, a way to harness the body’s immune system to target and destroy cancer cells.
Providence medical oncologist and Earle A. Chiles Research Institute assistant member BinBin Zheng, M.D., says:
‘If the liver cancer can’t be removed with minimally invasive procedures or surgery, the first treatment is usually immunotherapy. Unlike chemotherapy, which attacks cells directly, immunotherapy helps your own immune system fight the cancer.’
Meet the Providence scientists and clinical researchers driving breakthroughs in cancer research and care.”
More posts featuring Bernard A. Fox.